The company posted a consolidated net loss of ₹69.39 crore for the quarter, compared with a loss of ₹81.7 crore in the same period last year.
Revenue grew 17.4% year-on-year to ₹2,269.9 crore from ₹1,933.7 crore, while EBITDA surged 82.9% to ₹195.2 crore from ₹106.7 crore. EBITDA margin expanded to 8.6% from 5.5% a year earlier.
Management flags strong start to FY27
Chairperson Nandini Piramal said the company started FY27 on a strong note, with all three businesses delivering mid-to-high teens revenue growth along with meaningful EBITDA margin expansion.
She said the CDMO business recorded broad-based growth across India and overseas sites, supported by healthy request-for-proposal activity, order inflows and strong execution. The Complex Hospital Generics business maintained leadership in key therapies, gained traction in ex-US inhalation anesthesia markets and continued the integration of Kenalog.
Power Brands, e-commerce drive consumer healthcare growth
The Consumer Healthcare business continued to deliver robust growth, driven by its Power Brands, e-commerce, wider distribution, premiumisation and disciplined brand investments.
Within the consumer healthcare business, Power Brands grew 23% year-on-year and accounted for 53% of sales, while e-commerce revenue rose 40% and contributed 28% of sales. The company also launched the “i-choose” master brand for its women’s intimate care portfolio.
Piramal Pharma said premiumisation, disciplined pricing and cost-optimisation initiatives helped offset raw material inflation and supported EBITDA performance.The company added that it remains focused on delivering sustained revenue growth and further EBITDA expansion through FY27 while staying agile amid a dynamic external environment.
Shares of Piramal Pharma Limited closed 0.81% higher at ₹195 on the NSE on Wednesday, ahead of the company’s June quarter earnings announcement. The stock gained ₹1.57 during the session.
Also Read: Vedanta Oil & Gas swings to ₹945 crore Q1 profit after one-time gain
